Physician

Shahryar A. Ashouri, M.D.

According to 2025 Medicare claims, Shahryar Ashouri, M.D. (NPI: 1609946169) practices hematology/oncology in the Oxnard-Thousand Oaks-Ventura, CA market, with the plurality of this provider's patient population coming from Ventura, CA. This provider's primary affiliated billing organization is THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (NPI: 1235107566; TIN: 954373071) and primary practice location at 91361-3705.

Ashouri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,147 traditional Medicare patients, billed 276,773 HCPCS/CPT codes, and received $4,602,167 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 947 prescription claims across 277 beneficiaries totaling $2,561,545 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 79 claims. Open Payments data shows 2 records totaling $54. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,274,521 to $4,602,167. Similarly, Part D prescription costs have risen steadily, from $963,165 to $2,561,545. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $13,101 to $1,484.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	612	138,092	$2,274,521
2016	715	182,641	$2,553,939
2017	725	178,987	$2,947,394
2018	754	176,263	$2,952,561
2019	855	220,485	$4,025,016
2020	931	243,784	$4,080,186
2021	979	297,351	$4,162,185
2022	1,002	287,612	$3,231,525
2023	1,175	237,261	$3,870,332
2024	1,147	276,773	$4,602,167

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	198	1,085	$963,165
2016	231	1,332	$2,333,517
2017	234	1,461	$2,620,503
2018	254	1,439	$2,549,942
2019	289	1,498	$2,293,148
2020	286	1,563	$2,700,633
2021	286	1,430	$2,897,375
2022	307	1,381	$3,175,290
2023	323	1,278	$3,862,433
2024	277	947	$2,561,545

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	23	201	$34,622
2016	24	446	$43,664
2017	N/R	116	$14,294
2018	N/R	195	$15,805
2019	11	138	$11,751
2020	N/R	90	$3,956
2021	33	172	$8,466
2022	N/R	92	$3,795
2023	N/R	73	$13,123
2024	N/R	79	$1,866

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	195	404	$149
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	685	1,531	$102
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	404	644	$70
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	741	1,477	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	475	1,459	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	19	532	$734,181
Revlimid	Lenalidomide	16	406	$247,260
Tagrisso	Osimertinib Mesylate	12	360	$205,178
Xtandi	Enzalutamide	12	360	$164,130
Jakafi	Ruxolitinib Phosphate	17	510	$145,171

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	23	$668
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	16	$564
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	23	$433
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	17	$201

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$54	INTUITIVE SURGICAL, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shahryar A. Ashouri, M.D.?

Tedicare shows public-source Medicare data for Shahryar A. Ashouri, M.D. (NPI 1609946169), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shahryar A. Ashouri, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Shahryar A. Ashouri, M.D.?

Shahryar A. Ashouri, M.D. is linked to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (billing NPI 1235107566) in the available physician profile data.

Does Shahryar A. Ashouri, M.D. have Open Payments data?

Shahryar A. Ashouri, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.